Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting

NEXT STORY
Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in combination with anti-PD-1 Antibody Ezabenlimab, in Patients with Advanced Endometrium or Colorectal Tumors
PREV STORY
Valneva to Present and Hold Investor Meetings at the Guggenheim Vaccines and Infectious Disease Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Plus Therapeutics Announces Key RNL™ Development and cGMP Drug Manufacturing Collaboration Agreements

author_avatar
NASDAQ Market News

Worldwide Sports Medicine Industry to 2030 – Impact Analysis of COVID-19

author_avatar
NASDAQ Market News

Global In-Vitro Diagnostics Markets, 2020-2021 & 2030 – Instruments, Reagents, Software & Services

author_avatar
NASDAQ Market News